Grant: Discovery Grants Program - Individual
University of Toronto
$40,000.00
Using mathematical models to identify optimal critical process parameters for different mesenchymal stromal cell donors that dually maximizes fitness and expansion
EF 2024-25
Résumé
Background - The multimodal functions of mesenchymal stromal cells (MSCs) and their relative ease of isolation and expansion makes them attractive cell therapy candidates for numerous clinical indications. Despite nearly two decades of research and commercial investment, there are only a handful of global MSC products approved1, and none that are used clinically or commercially in Canada.
Problem - A major limitation has been the heterogeneity in primary donor tissue-derived MSC products, heterogeneity in the expansion kinetics of MSCs, heterogeneity in the quality attributes of the MSCs needed for clinical efficacy and heterogeneity in patient disease status. All these have confounded, and resulted in mixed clinical efficacy results, which has significantly dampened research and development enthusiasm for MSC clinical products.
Solution - We will use mathematical regression models, structural equation models and machine learning (ML) algorithms to tackle the heterogeneity, which is typically averaged with conventional research analytics. Specifically, we will use model predictions to identify donors which either a) require optimized manufacturing parameters, defined as critical processing parameters (CPP), or b) require genetic manipulation to increase their potency.
Another major limitation has been the lack of quantitative, sensitive characterization of MSC attributes tied to MSC clinical mechanism of action. Based on our previous NSERC DG grant, we identified quantitative, sensitive, functionally anchored critical quality attributes (CQAs) of MSCs2,3, which we have shown to independently correlate with clinical efficacy4, and thus define MSC "fitness".
Approach - i) Using these CQAs and Design of Experiment (DoE) approaches, we can generate donor-specific MSC data under different permutations of CPPs. Inputting this into our mathematical models and ML algorithms allows us to predict "fit" or "less fit/unfit" MSCs, and optimal CPP conditions to expand them so that they retain their fitness associated CQAs. Model predictions will be independently verified in 0.1 and 3L liquid-suspension bioreactors. ii) Using a mechanistic model, we will quantify relationship causalities between CPPs and CQAs, and identify donor-dependent variations. iii) Model predictions of unfit donors will be genetically engineered with small, non-coding microRNAs to increase their fitness, and tested to verify their improved expansion and fitness levels.
Impact - Our modeling and data science approaches allow us to predictably customize CPPs for individual MSC donors while maximizing both MSC expansion and MSC functional fitness. We use minimal experimental data to predict optimized CPP conditions that are donor-specific. This represents an important breakthrough for the field plagued with heterogeneity and will enable efficacious clinical and commercial translation for MSC products.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2024-04118
Name nom
Viswanathan, Sowmya
Department département
Institute of Biomedical Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1702
Research subject group en
Design and manufacturing
Research subject group fr
Conception et fabrication
Research subject en
Advanced manufacturing
Research subject fr
Méthodes de fabrication avancées
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Using mathematical models to identify optimal critical process parameters for different mesenchymal stromal cell donors that dually maximizes fitness and expansion
Keywords
mesenchymal stromal cells; mathematical models; liquid suspension bioreactor; design of experiment; critical quality attributes; critical process parameters; donor heterogeneity; structural equation models; machine learning models; genetic engineered mscs
Application summary
Background - The multimodal functions of mesenchymal stromal cells (MSCs) and their relative ease of isolation and expansion makes them attractive cell therapy candidates for numerous clinical indications. Despite nearly two decades of research and commercial investment, there are only a handful of global MSC products approved1, and none that are used clinically or commercially in Canada.
Problem - A major limitation has been the heterogeneity in primary donor tissue-derived MSC products, heterogeneity in the expansion kinetics of MSCs, heterogeneity in the quality attributes of the MSCs needed for clinical efficacy and heterogeneity in patient disease status. All these have confounded, and resulted in mixed clinical efficacy results, which has significantly dampened research and development enthusiasm for MSC clinical products.
Solution - We will use mathematical regression models, structural equation models and machine learning (ML) algorithms to tackle the heterogeneity, which is typically averaged with conventional research analytics. Specifically, we will use model predictions to identify donors which either a) require optimized manufacturing parameters, defined as critical processing parameters (CPP), or b) require genetic manipulation to increase their potency.
Another major limitation has been the lack of quantitative, sensitive characterization of MSC attributes tied to MSC clinical mechanism of action. Based on our previous NSERC DG grant, we identified quantitative, sensitive, functionally anchored critical quality attributes (CQAs) of MSCs2,3, which we have shown to independently correlate with clinical efficacy4, and thus define MSC "fitness".
Approach - i) Using these CQAs and Design of Experiment (DoE) approaches, we can generate donor-specific MSC data under different permutations of CPPs. Inputting this into our mathematical models and ML algorithms allows us to predict "fit" or "less fit/unfit" MSCs, and optimal CPP conditions to expand them so that they retain their fitness associated CQAs. Model predictions will be independently verified in 0.1 and 3L liquid-suspension bioreactors. ii) Using a mechanistic model, we will quantify relationship causalities between CPPs and CQAs, and identify donor-dependent variations. iii) Model predictions of unfit donors will be genetically engineered with small, non-coding microRNAs to increase their fitness, and tested to verify their improved expansion and fitness levels.
Impact - Our modeling and data science approaches allow us to predictably customize CPPs for individual MSC donors while maximizing both MSC expansion and MSC functional fitness. We use minimal experimental data to predict optimized CPP conditions that are donor-specific. This represents an important breakthrough for the field plagued with heterogeneity and will enable efficacious clinical and commercial translation for MSC products.